


**Product Name** : EIDD-2749  
**Cat. No.** : PC-25957  
**CAS No.** : 1613589-24-4  
**Molecular Formula** : C<sub>9</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>6</sub>  
**Molecular Weight** : 262.19  
**Target** : RSV  
**Solubility** : 10 mM in DMSO



## Biological Activity

4'-Fluorouridine (4'-FIU, EIDD-2749) is a broad-spectrum orally efficacious ribonucleoside analog that inhibits **RSV**, **SARS-CoV-2** and related RNA virus **LASV**, targets RSV and SARS-CoV-2 RdRP causes sequence-modulated transcriptional stalling.

4'-Fluorouridine (4'-FIU, EIDD-2749) shows potent dose-dependent activity against recombinant RSV A2-line19F (recRSV A2-L19F) and clinical RSV isolates with EC<sub>50</sub> of 0.61-1.2 uM.

4'-Fluorouridine (4'-FIU, EIDD-2749) inhibits RSV and paramyxovirus RdRP complex activity in cell-based minireplicon systems.

4'-Fluorouridine (4'-FIU, EIDD-2749) is efficiently anabolized in HAE cells and is efficacious in human airway epithelium organoids.

4'-Fluorouridine (4'-FIU, EIDD-2749) is orally efficacious in a therapeutic dosing regimen in a small-animal model of RSV infection.

4'-Fluorouridine (4'-FIU, EIDD-2749) is effective against SARS-CoV-2 in HAE and the ferret model.

4'-Fluorouridine (4'-FIU, EIDD-2749) also potently inhibits pathogenic arenaviruses Old World Lassa virus (**LASV**) and New World Junin virus (JUNV), in pig models of lethal disease.

## References

Schrell L, et al. **Antiviral Res.** 2025 Jan;233:106046. doi: 10.1016/j.antiviral.2024.106046.

Lieber CM, et al. **DNA Cell Biol.** 2022 Aug;41(8):699-704.

Welch SR, et al. **Sci Transl Med.** 2024 Nov 20;16(774):eado7034.

Sourimant J, et al. **Science.** 2022 Jan 14;375(6577):161-167.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com